Detalhe da pesquisa
1.
Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial.
Int J Clin Oncol
; 28(1): 163-174, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36534262
2.
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
Gynecol Oncol
; 164(2): 278-287, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34930617
3.
Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors.
Cancer Sci
; 108(9): 1834-1842, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28665051
4.
Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer.
Cancer Sci
; 108(11): 2213-2220, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28837250
5.
A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC).
Cancer Chemother Pharmacol
; 76(5): 1063-72, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26433581